Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
Figure 3
Growth inhibitory effects of drug treatments in MCF-7, T47D, SKBr3 and MDA-MB-231 cell line.
Cells were treated with trametinib, everolimus, NVP-BEZ235 or GSK2126458 for 3 days and [3H]-thymidine added for the last 6 hours. Results are shown as the mean ± standard error from duplicate experiments.